Dear shareholders and representatives,
As an independent director of Hubei Hendi Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company"), I, Xiang Guangya, have diligently fulfilled my responsibilities in accordance with the Company Law, the Administrative Measures for Independent Directors of Listed Companies, the Corporate Governance Guidelines for Listed Companies, and other relevant laws and regulations, as well as the Company’s Articles of Association and the Independent Director Work System. I have exercised my rights and obligations as an independent director with caution, independence, and objectivity, fully leveraging the role of independent directors to protect the legitimate rights and interests of the Company and all shareholders, especially minority shareholders. Below is my report on the performance of my duties as an independent director during the year 2025:
I. Basic Information
-
Work Experience and Professional Background
I, Xiang Guangya, hold Chinese nationality and do not have permanent residency abroad. I was born in November 1968 and hold a doctoral degree, serving as a professor. I previously worked as a teacher at Huangmei County No. 1 Middle School in Hubei Province and have been teaching at Huazhong University of Science and Technology since July 1995. I have obtained the qualification certificate for independent directors of listed companies and have served as an independent director of the Company since June 2020. -
No Circumstances Affecting Independence
During my tenure as an independent director, I have not held any position in the Company other than that of independent director, nor have I held any position in the Company’s major shareholders. There are no relationships with the Company or major shareholders that hinder my ability to make independent and objective judgments. I meet the relevant requirements regarding the independence of independent directors as stipulated in the Administrative Measures for Independent Directors of Listed Companies and the Self-Regulatory Guidelines for Listed Companies on the Shenzhen Stock Exchange.
II. Performance in 2025
In 2025, I attended the board and shareholder meetings convened by the Company. Prior to the meetings, I actively understood the Company’s operational status and communicated with relevant personnel to verify important matters. During the meetings, I carefully listened to and reviewed each proposal, participated in discussions, and provided reasonable suggestions, exercising my voting rights with a rigorous attitude to contribute to scientific decision-making for the Company. After the meetings, I continued to monitor the implementation of the proposals.
- Attendance at Board and Shareholder Meetings
(1) The meetings of the Company’s board and shareholders in 2025 were convened in accordance with legal procedures, and significant operational decisions and other major matters were carried out in compliance with relevant regulations, making the resolutions legal and effective.
(2) I personally attended all board meetings that I was required to attend in 2025 and voted in favor of all relevant proposals reviewed at the board meetings.
(3) In 2025, Hubei Hendi Pharmaceutical Co., Ltd. held three shareholder meetings, all of which I personally attended.